Influence of ORM1, PXR, CAR, CYP3A4 and CYP3A5 gene polymorphisms in mediating susceptibility risk to chronic myeloid leukaemia and response to imatinib mesylate therapy
Genetic polymorphisms are well recognized sources of individual differences in disease risk and treatment response. Associations between human genetic variants and predisposition to diseases and adverse events for different kinds of drug interactions with hundreds of protein like receptors, trans...
Main Author: | Maddin, Najlaa |
---|---|
Format: | Thesis |
Language: | English |
Published: |
2017
|
Subjects: | |
Online Access: | http://eprints.usm.my/43138/1/Dr._Najlaa_Maddin-24_pages.pdf |
Similar Items
-
An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia
by: Bee, P.C., et al.
Published: (2012) -
Association of CYP3A5*3, CYP3A4*18 & CYP2B6*6 polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
by: Chingiz Asadov, et al.
Published: (2023-01-01) -
Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience
by: Bee, P.C., et al.
Published: (2006) -
Influence of tert gene expression, telomerase activity and telomere length in relation to imatinib mesylate resistance in Malaysian chronic myeloid leukaemia patients
by: Shamshudin, Wati @ Hayati Mohd
Published: (2020) -
Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01)